

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA

复星医药

上海復星醫藥(集團)股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited. The following sets out the “Announcement in Relation to Acceptance of a Subsidiary’s Drug Registration Application” published by Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”) on the website of the Shanghai Stock Exchange, for your reference only. The following is a translation of the abovementioned announcement solely for the purpose of providing information. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

Shanghai, the PRC

12 July 2023

As at the date of this announcement, the executive directors of the Company are Mr. Wu Yifang, Mr. Wang Kexin, Ms. Guan Xiaohui and Mr. Wen Deyong; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui; and the independent non-executive directors of the Company are Ms. Li Ling, Mr. Tang Guliang, Mr. Wang Quandi and Mr. Yu Tze Shan Hailson.

* *for identification purposes only*

Stock code: 600196

Stock abbreviation: Fosun Pharma

No: Lin 2023-082

Bond code: 143422

Bond abbreviation: 18 Fosun 01

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Announcement in Relation to Acceptance of a Subsidiary's Drug Registration Application

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission and accept legal liability for the truthfulness, accuracy and completeness of the contents contained herein.

I. Overview

Recently, the drug registration application of Tenapanor tablets (the “**New Drug**”) of Shanghai Fosun Pharmaceutical Industrial Development Company Limited* (上海復星醫藥產業發展有限公司) (“**Fosun Pharma Industrial**”), a subsidiary of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (上海復星醫藥（集團）股份有限公司) (the “**Company**” and, together with its subsidiaries/units, the “**Group**”, the same applies below), which is used for the control of hyperphosphatemia in adult patients with chronic kidney disease (CKD) treated with hemodialysis, was accepted by the National Medical Products Administration.

II. Basic Information and Research Progress of the New Drug

The New Drug is a chemical drug . In December 2017, Fosun Pharma Industrial was granted an exclusive license from Ardelyx, Inc. (“**Ardelyx**”) for the clinical development and commercialization of the New Drug in the regions (i.e. Mainland China , Hong Kong and Macau Special Administrative Regions, hereinafter the same), and Ardelyx is still the owner of the New Drug in the regions.

As at the date of this announcement, the application of the New Drug which is used for the control of serum phosphorus in adults with CKD treated with hemodialysis is currently under FDA (i.e. U.S. Food and Drug Administration,

hereinafter the same) regulatory review.

Additionally, marketing application of the New Drug as a medicine for the treatment of irritable bowel syndrome with constipation has been approved by the U.S. FDA in September 2019 and was submitted in Hong Kong Special Administrative Region in March 2023. As at the date of this announcement, the New Drug completed the study of phase I clinical trials for this indication in China (hereinafter excluding Hong Kong, Macau and Taiwan region for the purpose of this announcement, the same applies below).

As at the date of this announcement, the drugs for the control of hyperphosphatemia in adults patients with CKD treated with hemodialysis that have been launched in China mainly include Renvela[®] (诺维乐[®]) (Sevelamer Carbonate Tablets) of Genzyme Europe B.V. and Fosrenol[®] (福斯利诺[®]) (Lanthanum Carbonate Chewable Tablets) of Shire Pharmaceuticals Ireland Limited, etc. According to the latest data from IQVIA CHPA (provided by IQVIA, a professional information and strategic consulting service provider for the pharmaceutical and health industry, IQVIA CHPA data represents the drug sales market of hospitals with over 100 beds in China. The actual sales of different drugs may vary from the IQVIA CHPA data to varying degrees due to their different sales distribution channels), the sales of Renvela[®] (诺维乐[®]) and Fosrenol[®] (福斯利诺[®]) amounted to approximately RMB 1,206 million in 2022 in China.

As at the end of May 2023, the Group has invested approximately RMB134.81 million (unaudited; licensed fees included) in total in the research and development of the New Drug at this stage.

III. Risk Warning

The New Drug is subject to, among others, the obtainment of drug registration approval before it can be commercialized in China. This acceptance of the drug registration application is not expected to have a material impact on the current results of the Group.

Due to the characteristics of the pharmaceutical products industry, the specific sales performance of the pharmaceutical products may be affected by factors including, but not limited to, the demand for medication, market competition and sales channels, and is subject to considerable uncertainty. Investors should take note

of the investment risks.

Announcement is hereby made.

Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

12 July 2023

*For identification purposes only